Genmab's EPKINLY plus R2 shows 79% reduced disease progression risk in lymphoma trial

Genmab reported compelling Phase 3 EPCORE FL-1 data for EPKINLY (epcoritamab-bysp) + R2 in relapsed/refractory follicular lymphoma, showing a 79% reduction in risk of progression or death versus R2 alone, overall response rate 95% vs 79%, complete response 83% vs 50%, and 12‑month duration of response 89% vs 49%, albeit with higher grade 3–4 TEAEs (90.1% vs 67.6%). The FDA approved EPKINLY + R2 for second‑line follicular lymphoma in November 2025, marking the first bispecific approval for that setting. Genmab also closed a $2.5bn senior note offering ($1.5bn secured due 2032, $1.0bn unsecured due 2033) to finance its pending Merus acquisition, and H.C. Wainwright raised its price target to $41 while maintaining a Buy rating.

Analysis

Market structure: Genmab (GMAB) and commercialization partner AbbVie (ABBV) are primary beneficiaries — epcoritamab as the first bispecific approved in 2L follicular lymphoma can reprice the second-line market for ~15,000 U.S. patients annually, favoring higher ASP and supportive-care spend; incumbents using R2 face volume loss and pricing pressure. The $2.5bn bond raise to finance Merus increases Genmab’s leverage and creates a near-term credit overhang that will cap equity upside until integration and early sales visibility arrive.

Risk assessment: Near-term risks (days–weeks) include sell-the-news on financing and initial formulary decisions; medium-term (3–12 months) risks are payer pushback on label breadth and real-world safety given 90% grade 3/4 AEs; long-term (1–3 years) risks include manufacturing scale failures, adverse subgroup readouts, or pricing concessions that erode modeled margins by >30%. Hidden dependencies: AbbVie’s commercialization execution, supply-chain scale, and the contingent liabilities from Merus integration are gating factors — monitor covenant triggers and 2032/33 note spreads closely.

Trade implications: Direct plays — equity exposure to GMAB is asymmetric upside but debt-overhang and safety profile argue for hedged entry: consider small long core position plus puts or call spreads to limit downside; avoid buying GMAB unsecured paper until spreads tighten below 300bps over swaps. Cross-asset: expect GMAB equity IV to stay elevated; GMAB bond yields and CDS are actionable if they exceed 6.5–7.0% (buy protection/short bonds).

Contrarian angles: Consensus may underweight uptake constraints from high AE rates and payer restrictions — widespread 90% grade 3/4 AEs is a real adoption brake that could confine penetration to high-risk subsets (reducing addressable market by >40%). Historical parallel: early CAR‑T approvals showed strong initial enthusiasm followed by payer-driven utilization limits; a similar moderation could make current bullish pricing targets (e.g., H.C. Wainwright’s uplift) over-optimistic in 12–24 months.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in GMAB (ticker GMAB) with a 12–18 month horizon; immediately buy a 12-month put ~30% OTM sized to cover 50% of position to cap tail loss. Exit/trim if stock rises +50% or if 12-month annualized U.S. sales run-rate < $200m after first two commercial quarters.
• Do not add exposure to Genmab 2032/2033 notes today; consider shorting GMAB senior unsecured paper or buying CDS protection if the 2033 yield >6.5% or spread >300bps versus swaps — target capture of credit widening while avoiding equity-only risk.
• Deploy a directional options trade: buy a 12–18 month GMAB call vertical (e.g., buy 2027 call 30% OTM, sell nearer-dated call to fund) sized 0.5–1% portfolio to play adoption upside while limiting premium. Close if implied vol >80% or after first two quarterly sales prints.
• If MRUS (Merus) arbitrage spread >4% between announced deal price and market, evaluate a merger-arb long MRUS (cash-secured) with 6–12 month hold; otherwise avoid MRUS exposure due to financing-related execution risk. Monitor payer coverage decisions and first 90-day launch uptake as binary catalysts to increase/decrease exposure.